Advertisement

Sentinel Lymph Node Biopsy in Breast Cancer: Current Status and Recent Progress

  • Amina Maimaitiaili
  • Zhenyu Liu
  • Di Wu
  • Zhimin FanEmail author
Review Article
  • 13 Downloads

Abstract

Sentinel lymph node biopsy (SLNB) is a standard procedure used to evaluate the status of axillary lymph nodes (ALNs) that are clinically tumor-free in patients with early-stage breast cancer. Recent research on SLNB has led to continual improvements in the scope of application, accuracy in information provided, and relevance of the results for subsequent treatment. This review is based on selective searches of the Springer Publishing Company and PubMed databases for articles about progress and developments of SLNB in patients with breast cancer. The main purposes are to summarize the current status and established indications for SLNB, identify specific topics that are still under debate, and suggest specific areas where further studies are most needed.

Keywords

Sentinel lymph node biopsy Axillary lymph node dissection Breast cancer Neoadjuvant chemotherapy Isolated tumor cells Micrometastases 

Notes

Acknowledgments

We are grateful to our colleagues and their families for supporting the work.

Author Contribution

All authors have read and approved the submission of the manuscript.

Compliance with Ethical Standards

Conflict of interest

The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language, except as an abstract. The authors declare that they have no competing interests.

References

  1. 1.
    Desantis CE, Bray F, Ferlay J et al (2015) International variation in female breast cancer incidence and mortality rates.[J]. Cancer Epidemiol Biomark Prev 24(10):1495–1506CrossRefGoogle Scholar
  2. 2.
    Gherghe M, Bordea C, Blidaru A (2014) Sentinel lymph node biopsy (SLNB) vs. axillary lymph node dissection (ALND) in the current surgical treatment of early stage breast cancer.[J]. J Med Life 8(2):176–180Google Scholar
  3. 3.
    Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009[J]. Ann Oncol 20(8):1319–1329(11)CrossRefGoogle Scholar
  4. 4.
    Faries MB, Bedrosian I, Reynolds C et al (2000) Active macromolecule uptake by lymph node antigen-presenting cells: a novel mechanism in determining sentinel lymph node status [J]. Ann Surg Oncol 7(2):98–105CrossRefGoogle Scholar
  5. 5.
    Manca G, Tardelli E, Rubello D, Gennaro M, Marzola MC, Cook GJ, Volterrani D (2016) Sentinel lymph node biopsy in breast cancer: a technical and clinical appraisal.[J]. Nucl Med Commun 37:570–576CrossRefGoogle Scholar
  6. 6.
    Motomura K (2015) Sentinel node biopsy for breast cancer: past, present, and future.[J]. Breast Cancer 22:1–9CrossRefGoogle Scholar
  7. 7.
    Palesty JA, Foster JM, Hurd TC et al (2006) Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer [J]. J Surg Oncol 93(2):129–132CrossRefGoogle Scholar
  8. 8.
    Janni W, Kühn T, Schwentner L, Kreienberg R, Fehm T, Wöckel A (2014) Sentinel node biopsy and axillary dissection in breast cancer: the evidence and its limits [J]. Dtsch Arztebl Int 111(14):244–249PubMedPubMedCentralGoogle Scholar
  9. 9.
    Soares EWS, Nagai HM, Bredt LC et al (2014) Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients [J]. World J Surg Oncol 12(1):1–8CrossRefGoogle Scholar
  10. 10.
    Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer [J]. N Engl J Med 349(6):546–553CrossRefGoogle Scholar
  11. 11.
    Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer [J]. J Clin Oncol 23(30):7703CrossRefGoogle Scholar
  12. 12.
    Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial : The Lancet Oncology [J]. Lancet Oncol 8(10):881–888CrossRefGoogle Scholar
  13. 13.
    Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, Benson AB 3rd, Bosserman LD, Burstein HJ, Cody H 3rd, Hayman J, Perkins CL, Podoloff DA, Giuliano AE (2014) American Society of Clinical Oncology Clinical Practice. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.[J]. J Clin Oncol 32(13):1365–1383CrossRefGoogle Scholar
  14. 14.
    Taguchi Y, Yasojima H, Masuda H et al (2014) 171. The long-term prognosis of sentinel lymph node-positive breast cancer patients without axillary dissection [J]. Clin Orthop Relat Res 40(11):1–31Google Scholar
  15. 15.
    Giuliano AE, Ballman KV, Mccall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial.[J]. JAMA 318(10):918CrossRefGoogle Scholar
  16. 16.
    Giuseppe Canavese MD, Paolo Bruzzi MD…. Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial[J]. Annals of Surgical Oncology, 23(8):2494–2500.CrossRefGoogle Scholar
  17. 17.
    Bilimoria KY, Bentrem DJ, Hansen NM et al (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer [J]. J Clin Oncol 27(18):2946–2953CrossRefGoogle Scholar
  18. 18.
    (2017) Sentinel lymph node biopsy for patients with early stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(5):561–564.  https://doi.org/10.1200/JCO.2016.71.0947 CrossRefGoogle Scholar
  19. 19.
    Meretoja T, Leidenius et al (2013) Re: International multicenter tool to predict the risk of nonsentinel;node metastases in breast cancer response [J]. J Natl Cancer Inst 105(19):1514–1514CrossRefGoogle Scholar
  20. 20.
    Maimaitiaili A, Wu D, Liu Z, Liu H, Muyiduli X, Fan Z. Analysis of factors related to non-sentinel lymph node metastasis in 296 sentinel lymph node-positive Chinese breast cancer patients [published correction appears in Cancer Biol Med. 2018 Nov;15(4):478].Cancer Biol Med. 2018;15(3):282–289. doi:10.20892/j.issn.2095–3941.2018.0023Google Scholar
  21. 21.
    Dingemans SA, Rooij PD, van der Vuurst de Vries RM et al (2016) Validation of six nomograms for predicting non-sentinel lymph node metastases in a Dutch breast cancer population [J]. Ann Surg Oncol 23(2):477–481CrossRefGoogle Scholar
  22. 22.
    Melissa Pilewskie, Maria Karsten, Julia Radosa, et al. Is Sentinel Lymph Node Biopsy Indicated at Completion Mastectomy for Ductal Carcinoma In Situ?[J]. Annals of Surgical Oncology, 2016:1-6.Google Scholar
  23. 23.
    Roozendaal LMV, Goorts B, Klinkert M et al (2016) Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy [J]. Breast Cancer Res Treat 156:517–525CrossRefGoogle Scholar
  24. 24.
    Krontiras H, Bland KI (2003) When is sentinel node biopsy for breast cancer contraindicated?[J]. Surg Oncol 12(3):207–210CrossRefGoogle Scholar
  25. 25.
    Gropper AB, Calvillo KZ, Dominici L et al (2014) Sentinel lymph node biopsy in pregnant women with breast cancer.[J]. Ann Surg Oncol 21(8):2506–2511CrossRefGoogle Scholar
  26. 26.
    Han S N , Amant F , Sangalli C , et al. 266pd_prsentinel lymph node biopsy for breast cancer treatment during pregnancy - on behalf of the international network of cancer, infertility and pregnancy (incip) and the german breast group (gbg)[j]. Annals of Oncology, 2014, 25(4 (Supplement)).Google Scholar
  27. 27.
    Hunt KK (2009) Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible and accurate in women with advanced breast cancer?[J]. Curr Breast Cancer Rep 1(2):65–67CrossRefGoogle Scholar
  28. 28.
    Mamtani, Anita, Barrio, Andrea V, King, Tari A,et al. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study[J]. Annals of Surgical Oncology, 23(11):3467-3474.CrossRefGoogle Scholar
  29. 29.
    Thorsten K, Ingo B, Tanja F et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study [J]. Lancet Oncol 14(7):609–618CrossRefGoogle Scholar
  30. 30.
    Gallant E, Ewing C, Wong J, et al. Abstract P3-01-10: Sentinel lymph node biopsy after neoadjuvant chemotherapy for patients with clinically node-positive breast cancer: A single institution retrospective evaluation[J]. 2016, 76(4 Supplement):P3-01-10-P3-01-10.Google Scholar
  31. 31.
    Kashiwagi S, Onoda N, Asano Y et al (2015) Ambulatory sentinel lymph node biopsy preceding neoadjuvant therapy in patients with operable breast cancer: a preliminary study [J]. World J Surg Oncol 13(1):1–6CrossRefGoogle Scholar
  32. 32.
    Caudle AS, Yang W, Mittendorf EA, et al. Targeted axillary dissection improves axillary evaluation following neoadjuvant chemotherapy in node positive patients [C]// Cancer Symposium of the Society-Of-Surgical-Oncology. 2015:S6–S6.Google Scholar
  33. 33.
    Ahmed M , Douek M . Targeted axillary dissection after neoadjuvant therapy in breast cancer[J]. British Journal of Surgery, 2017.Google Scholar
  34. 34.
    Tomasz N, Andrzej K, Wojciech P et al (2016) Imaging methods for the local lymphatic system of the axilla in early breast cancer in patients qualified for sentinel lymph node biopsy:[J]. Menopausal Rev 15(1):52–55Google Scholar
  35. 35.
    Iii HSC, Fey J, Akhurst T et al (2001) Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures [J]. Ann Surg Oncol 8(1):13–19CrossRefGoogle Scholar
  36. 36.
    Hung WK, Chan CM, Ying M et al (2006) Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer [J]. J Electron Microsc 92(12):1494–1497Google Scholar
  37. 37.
    He PS, Li F, Li GH et al (2016) The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review [J]. BMC Cancer 16(1):1–12CrossRefGoogle Scholar
  38. 38.
    Sugie T, Kinoshita T, Masuda N et al (2015) Evaluation of the clinical utility of the ICG fluorescence method compared with the radioisotope method for sentinel lymph node biopsy in breast cancer [J]. Ann Surg Oncol 23(1):635–649Google Scholar
  39. 39.
    Ahmed M, Purushotham AD, Douek M (2014) Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review [J]. Lancet Oncol 15(8):e351–e362CrossRefGoogle Scholar
  40. 40.
    Deai T, Matumoto H, et al. Practice of fluorescence navigation surgery using indocyanine green for sentinel lymph node biopsy in breast cancer [M]// ICG Fluorescence Imaging and Navigation Surgery. Springer Japan, 2016.Google Scholar
  41. 41.
    Galimberti V, Cole BF, Viale G et al (2018) Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled, phase 3 triall [J]. Lancet Oncol 19(10):1385–1393CrossRefGoogle Scholar
  42. 42.
    Galimberti V, Botteri E, Chifu C et al (2012) Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? [J]. Breast Cancer Res Treat 131(3):819–825CrossRefGoogle Scholar
  43. 43.
    Gatzemeier W, Mann GB (2013) Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND) – ACOSOG Z0011 results and beyond [J]. Breast 22(3):211–216CrossRefGoogle Scholar
  44. 44.
    Shahkhan M, Boughey JC (2012) Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.[J]. Cancer Control 19(4):267–276CrossRefGoogle Scholar

Copyright information

© Association of Surgeons of India 2019

Authors and Affiliations

  • Amina Maimaitiaili
    • 1
  • Zhenyu Liu
    • 1
  • Di Wu
    • 1
  • Zhimin Fan
    • 1
    Email author
  1. 1.Department of Breast SurgeryFirst Hospital of Jilin UniversityChangchunChina

Personalised recommendations